TBCRC 041 Randomized Phase II Trial to Evaluate Alisertib Alone or Combined with Fulvestrant in Women with Advanced, Hormone-Receptor Positive (HR+) Breast Cancer
Administered By
Awarded By
Contributors
- Marcom, Paul Kelly Principal Investigator
Start/End
- March 20, 2019 - October 2, 2023